First Manhattan’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

First Manhattan’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-453,091	Closed	-$5.47M	–	1466
2019 Q1	$5.47M	Sell	453,091 -596,443	-57%	-$8.79M	0.03%	226
2018 Q4	$13.2M	Buy	1,049,534 +484,739	+86%	+$6.69M	0.08%	137
2018 Q3	$8.38M	Buy	+564,795	New	+$8.89M	0.04%	209
2018 Q1	–	Sell	-17,900	Closed	-$463K	–	1485
2017 Q4	$463K	Sell	17,900 -51,000	-74%	-$1.03M	﹤0.01%	561
2017 Q3	$1.02M	Buy	+68,900	New	+$1,000K	0.01%	438

Other funds holding CNCE

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

First Manhattan's CNCE Position: Q2 2019 in Review

First Manhattan sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 453,091 shares — an estimated $5.47M sold.

First Manhattan first reported a position in CNCE in Q3 2017 and held it in 5 quarters. The position peaked at $13.2M in Q4 2018. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

First Manhattan reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
First Manhattan sold 453,091 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $5.47M.
First Manhattan first reported a position in Concert Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
First Manhattan's Concert Pharmaceuticals, Inc. position peaked at $13.2M in Q4 2018.
87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on First Manhattan's 13F filing for Q2 2019, filed 16 Aug 2019.